SIGMART

Sigmart Adverse Events Reported to the FDA Over Time

How are Sigmart adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Sigmart, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Sigmart is flagged as the suspect drug causing the adverse event.

Most Common Sigmart Adverse Events Reported to the FDA

What are the most common Sigmart adverse events reported to the FDA?

Liver Disorder	30 (3.53%)
Pyrexia	18 (2.12%)
Alanine Aminotransferase Increased	16 (1.88%)
Aspartate Aminotransferase Increase...	16 (1.88%)
Hepatic Function Abnormal	14 (1.65%)
Blood Alkaline Phosphatase Increase...	13 (1.53%)
Liver Function Test Abnormal	13 (1.53%)
White Blood Cell Count Decreased	13 (1.53%)
Asthma	12 (1.41%)
Loss Of Consciousness	12 (1.41%)
Cerebral Infarction	11 (1.29%)
	Show More
Gamma-glutamyltransferase Increased	10 (1.18%)
Agranulocytosis	9 (1.06%)
Coronary Arterial Stent Insertion	9 (1.06%)
Septic Shock	9 (1.06%)
Toxic Skin Eruption	9 (1.06%)
Ventricular Fibrillation	9 (1.06%)
Acute Generalised Exanthematous Pus...	8 (.94%)
Angina Pectoris	8 (.94%)
Cardiac Failure	8 (.94%)
Coronary Artery Restenosis	8 (.94%)
Coronary Artery Stenosis	8 (.94%)
Interstitial Lung Disease	8 (.94%)
Jaundice	8 (.94%)
Acute Respiratory Distress Syndrome	7 (.82%)
Arteriospasm Coronary	7 (.82%)
Blood Lactate Dehydrogenase Increas...	7 (.82%)
Blood Magnesium Decreased	7 (.82%)
Cardiovascular Disorder	7 (.82%)
Catheterisation Cardiac	7 (.82%)
Contusion	7 (.82%)
Coronary Angioplasty	7 (.82%)
Electrocardiogram St Segment Depres...	7 (.82%)
Electrocardiogram St Segment Elevat...	7 (.82%)
Exercise Electrocardiogram Abnormal	7 (.82%)
Exercise Test Abnormal	7 (.82%)
Fall	7 (.82%)
Gingival Swelling	7 (.82%)
Haemodialysis	7 (.82%)
Mouth Ulceration	7 (.82%)
Myocardial Ischaemia	7 (.82%)
Pancytopenia	7 (.82%)
Pneumonia	7 (.82%)
Pruritus	7 (.82%)
Renal Impairment	7 (.82%)
Thrombocytopenia	7 (.82%)
Ventricular Extrasystoles	7 (.82%)
Chest Discomfort	6 (.71%)
Condition Aggravated	6 (.71%)
Drug Level Increased	6 (.71%)
Granulocytopenia	6 (.71%)
Hepatocellular Injury	6 (.71%)
Hyperkalaemia	6 (.71%)
Hypoxia	6 (.71%)
In-stent Coronary Artery Restenosis	6 (.71%)
Lymphocyte Stimulation Test Positiv...	6 (.71%)
Nasopharyngitis	6 (.71%)
Platelet Count Decreased	6 (.71%)
Renal Failure Acute	6 (.71%)
Thrombocytopenic Purpura	6 (.71%)
Blood Pressure Decreased	5 (.59%)
Disseminated Intravascular Coagulat...	5 (.59%)
Dyspnoea	5 (.59%)
Eosinophilia	5 (.59%)
Malaise	5 (.59%)
Rash	5 (.59%)
Urine Output Decreased	5 (.59%)
Anorexia	4 (.47%)
Cardio-respiratory Arrest	4 (.47%)
Diarrhoea	4 (.47%)
Eosinophilic Pneumonia	4 (.47%)
Epilepsy	4 (.47%)
Escherichia Infection	4 (.47%)
Gingival Erythema	4 (.47%)
Haemoglobin Decreased	4 (.47%)
Hepatitis Cholestatic	4 (.47%)
Pulmonary Oedema	4 (.47%)
Anuria	3 (.35%)
Arteriovenous Fistula	3 (.35%)
Blood Bilirubin Increased	3 (.35%)
Blood Creatine Phosphokinase Increa...	3 (.35%)
C-reactive Protein Increased	3 (.35%)
Cardiac Disorder	3 (.35%)
Chest X-ray Abnormal	3 (.35%)
Dermatitis Exfoliative	3 (.35%)
Drug Eruption	3 (.35%)
Drug Ineffective	3 (.35%)
Eosinophil Count Increased	3 (.35%)
Gingivitis	3 (.35%)
Haematocrit Decreased	3 (.35%)
Hepatic Infiltration Eosinophilic	3 (.35%)
Histiocytosis Haematophagic	3 (.35%)
Infection	3 (.35%)
Monoplegia	3 (.35%)
Neutropenia	3 (.35%)
Neutrophil Count Decreased	3 (.35%)
Pain In Extremity	3 (.35%)
Pleural Effusion	3 (.35%)
Purpura	3 (.35%)
Rash Papular	3 (.35%)
Stent Placement	3 (.35%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Sigmart, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Sigmart is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Sigmart

What are the most common Sigmart adverse events reported to the FDA?

Hepatic And Hepatobiliary	73 (8.59%)
Hepatobiliary	59 (6.94%)
Epidermal And Dermal Conditions	52 (6.12%)
Cardiac And Vascular Investigations	44 (5.18%)
Hematology Investigations	42 (4.94%)
Coronary Artery	37 (4.35%)
Cardiac Arrhythmias	30 (3.53%)
Infections - Pathogen Unspecified	30 (3.53%)
Lower Respiratory Tract Disorders	25 (2.94%)
White Blood Cell	25 (2.94%)
Enzyme	24 (2.82%)
	Show More
Body Temperature Conditions	18 (2.12%)
Renal Disorders	18 (2.12%)
Neurological	17 (2%)
Vascular Therapeutic Procedures	17 (2%)
Procedural And Device Related Injur...	16 (1.88%)
Injuries	15 (1.76%)
Central Nervous System Vascular	14 (1.65%)
Oral Soft Tissue Conditions	14 (1.65%)
Respiratory	14 (1.65%)
Platelet	13 (1.53%)
Bronchial Disorders	12 (1.41%)
Heart Failures	12 (1.41%)
Cardiac Disorder Signs	11 (1.29%)
Renal And Urinary Tract Investigati...	9 (1.06%)
Hematological And Lymphoid Tissue T...	8 (.94%)
Anemias Nonhemolytic And Marrow Dep...	7 (.82%)
Decreased And Nonspecific Blood Pre...	7 (.82%)
Dental And Gingival Conditions	7 (.82%)
Toxicology And Therapeutic Drug Mon...	7 (.82%)
Water, Electrolyte And Mineral	7 (.82%)
Bacterial Infectious	6 (.71%)
Coagulopathies And Bleeding Diathes...	6 (.71%)
Electrolyte And Fluid Balance Condi...	6 (.71%)
Gastrointestinal Signs	6 (.71%)
Therapeutic And Nontherapeutic Effe...	5 (.59%)
Appetite And General Nutritional	4 (.47%)
Fatal Outcomes	4 (.47%)
Gastrointestinal Motility And Defec...	4 (.47%)
Microbiology And Serology	4 (.47%)
Musculoskeletal And Connective Tiss...	4 (.47%)
Nephropathies	4 (.47%)
Seizures	4 (.47%)
Cardiac Therapeutic Procedures	3 (.35%)
Deliria	3 (.35%)
Gastrointestinal Ulceration And Per...	3 (.35%)
Hematopoietic Neoplasms	3 (.35%)
Medication Errors	3 (.35%)
Metabolic, Nutritional And Blood Ga...	3 (.35%)
Movement Disorders	3 (.35%)
Pleural	3 (.35%)
Protein And Chemistry Analyses	3 (.35%)
Respiratory And Pulmonary Investiga...	3 (.35%)
Skin Vascular Abnormalities	3 (.35%)
Therapeutic Procedures And Supporti...	3 (.35%)
Vascular	3 (.35%)
Embolism And Thrombosis	2 (.24%)
Gallbladder	2 (.24%)
Gastrointestinal	2 (.24%)
Gastrointestinal Conditions	2 (.24%)
Glucose Metabolism Disorders	2 (.24%)
Headaches	2 (.24%)
Immunodeficiency Syndromes	2 (.24%)
Lipid Metabolism	2 (.24%)
Muscle	2 (.24%)
Myocardial	2 (.24%)
Pericardial	2 (.24%)
Pulmonary Vascular	2 (.24%)
Skin And Subcutaneous Tissue	2 (.24%)
Structural Brain	2 (.24%)
Allergic Conditions	1 (.12%)
Anxiety Disorders	1 (.12%)
Changes In Physical Activity	1 (.12%)
Connective Tissue Disorders	1 (.12%)
Gastrointestinal Neoplasms Malignan...	1 (.12%)
Leukemias	1 (.12%)
Miscellaneous And Site Unspecified ...	1 (.12%)
Neuromuscular	1 (.12%)
Penile And Scrotal Disorders	1 (.12%)
Peritoneal And Retroperitoneal Cond...	1 (.12%)
Physical Examination Topics	1 (.12%)
Plasma Cell Neoplasms	1 (.12%)
Urinary Tract Signs	1 (.12%)
Vascular Hypertensive	1 (.12%)
Viral Infectious	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Sigmart, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Sigmart is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.